newsfilter
← Latest News
GlobeNewswire·

Alaunos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Generated cutting-edge translational data demonstrating safety, persistence and functionality of infused TCR-T cells in the tumor microenvironment; provides support for next generation TCR-T effortsAdvancing TCR-T